Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Alessandra Romano

Showing results (151-160 of 165) with videos related to

Pageof 17
Sort By:
Cancer Medicine|March 17, 2026
Next Generation Flow and Next Generation Sequencing for Measurable Residual Disease Assessment in Multiple Myeloma Patients: A Real-Life Italian Multicenter Harmonization ExperienceStefania Oliva, Marina Martello, Elona Saraci, et al.
British Journal of Haematology|July 17, 2021
COVID-19 elicits an impaired antibody response against SARS-CoV-2 in patients with haematological malignanciesFrancesco Passamonti, Alessandra Romano, Marco Salvini, et al.
Hematological Oncology|October 20, 2022
SARS-CoV-2 infection in patients with chronic lymphocytic leukemia: The Italian Hematology Alliance on COVID-19 cohortMichele Merli, Isacco Ferrarini, Francesco Merli, et al.
Oncotarget|December 7, 2017
Italian real life experience with brentuximab vedotin: results of a large observational study on 234 relapsed/refractory Hodgkin's lymphomaCinzia Pellegrini, Alessandro Broccoli, Alessandro Pulsoni, et al.
Annals of Hematology|October 7, 2025
Continous or fixedcarfilzomib, lenalidomide and dexamethasone (krd) for relapsed-refractory multiple myeloma: long-term follow-up from a multicenter, retrospective real-life surveyfrom European myeloma network (emn) ItalyConcetta Conticello, Vittorio Del Fabro, Alessandra Romano, et al.
Haematologica|August 5, 2017
Italian real-life experience with brentuximab vedotin: results of a large observational study of 40 cases of relapsed/refractory systemic anaplastic large cell lymphomaAlessandro Broccoli, Cinzia Pellegrini, Alice Di Rocco, et al.
Cancer|January 24, 2023
AVALON: The Italian cohort study on real-life efficacy of hypomethylating agents plus venetoclax in newly diagnosed or relapsed/refractory patients with acute myeloid leukemiaElisabetta Todisco, Cristina Papayannidis, Nicola Fracchiolla, et al.
Hematological Oncology|July 20, 2022
Secondary infections worsen the outcome of COVID-19 in patients with hematological malignancies: A report from the ITA-HEMA-COVPatrizia Zappasodi, Chiara Cattaneo, Virginia Valeria Ferretti, et al.
Blood Advances|October 13, 2021
A prognostic model for patients with lymphoma and COVID-19: a multicentre cohort studyCarlo Visco, Luigi Marcheselli, Roberto Mina, et al.
International Journal of Antimicrobial Agents|August 15, 2023
Molnupiravir compared to nirmatrelvir/ritonavir for COVID-19 in high-risk patients with haematological malignancy in Europe. A matched-paired analysis from the EPICOVIDEHA registryJon Salmanton-García, Francesco Marchesi, Philipp Koehler, et al.
Pageof 17

Showing results (151-160 of 165) with videos related to

Sort By:
Pageof 17
Cancer Medicine|March 17, 2026
Next Generation Flow and Next Generation Sequencing for Measurable Residual Disease Assessment in Multiple Myeloma Patients: A Real-Life Italian Multicenter Harmonization ExperienceStefania Oliva, Marina Martello, Elona Saraci, et al.
British Journal of Haematology|July 17, 2021
COVID-19 elicits an impaired antibody response against SARS-CoV-2 in patients with haematological malignanciesFrancesco Passamonti, Alessandra Romano, Marco Salvini, et al.
Hematological Oncology|October 20, 2022
SARS-CoV-2 infection in patients with chronic lymphocytic leukemia: The Italian Hematology Alliance on COVID-19 cohortMichele Merli, Isacco Ferrarini, Francesco Merli, et al.
Oncotarget|December 7, 2017
Italian real life experience with brentuximab vedotin: results of a large observational study on 234 relapsed/refractory Hodgkin's lymphomaCinzia Pellegrini, Alessandro Broccoli, Alessandro Pulsoni, et al.
Annals of Hematology|October 7, 2025
Continous or fixedcarfilzomib, lenalidomide and dexamethasone (krd) for relapsed-refractory multiple myeloma: long-term follow-up from a multicenter, retrospective real-life surveyfrom European myeloma network (emn) ItalyConcetta Conticello, Vittorio Del Fabro, Alessandra Romano, et al.
Haematologica|August 5, 2017
Italian real-life experience with brentuximab vedotin: results of a large observational study of 40 cases of relapsed/refractory systemic anaplastic large cell lymphomaAlessandro Broccoli, Cinzia Pellegrini, Alice Di Rocco, et al.
Cancer|January 24, 2023
AVALON: The Italian cohort study on real-life efficacy of hypomethylating agents plus venetoclax in newly diagnosed or relapsed/refractory patients with acute myeloid leukemiaElisabetta Todisco, Cristina Papayannidis, Nicola Fracchiolla, et al.
Hematological Oncology|July 20, 2022
Secondary infections worsen the outcome of COVID-19 in patients with hematological malignancies: A report from the ITA-HEMA-COVPatrizia Zappasodi, Chiara Cattaneo, Virginia Valeria Ferretti, et al.
Blood Advances|October 13, 2021
A prognostic model for patients with lymphoma and COVID-19: a multicentre cohort studyCarlo Visco, Luigi Marcheselli, Roberto Mina, et al.
International Journal of Antimicrobial Agents|August 15, 2023
Molnupiravir compared to nirmatrelvir/ritonavir for COVID-19 in high-risk patients with haematological malignancy in Europe. A matched-paired analysis from the EPICOVIDEHA registryJon Salmanton-García, Francesco Marchesi, Philipp Koehler, et al.
Pageof 17